S-1–Induced Lacrimal Drainage Obstruction and Its Association with Ingredients/Metabolites of S-1 in Tears and Plasma: A Prospective Multi-institutional Study
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose This prospective study was conducted to determine the incidence of lacrimal drainage obstruction (LDO) during S-1 chemotherapy and evaluate the association between the development of LDO and the concentrations of ingredients/metabolites of S-1 in tears and plasma. Materials and Methods A total of 145 patients with gastric cancer who received adjuvant S-1 therapy were enrolled. Ophthalmologic examinations were performed regularly during S-1 chemotherapy. Concentrations of tegafur, 5-chloro-2,4-dihydroxypyridine (CDHP), and 5-fluorouracil at steady-state trough level were measured in both tears and plasma. Results Fifty-three patients (37%) developed LDO. The median time to the onset of LDO was 10.9 weeks, and LDO developed most frequently in the nasolacrimal duct. Univariable analyses revealed that an older age (! 70 years), creatinine clearance rate (Ccr) < 80 mL/min, 5-fluorouracil concentration in plasma ! 22.3 ng/mL (median), CDHP concentration in plasma ! 42.0 ng/mL (median), and tegafur concentration in tears ! 479.2 ng/mL (median) were related to increased development of LDO. Multivariable analysis indicated that a high plasma 5-fluorouracil concentration was predictive of increased development of LDO (hazard ratio, 2.02; p=0.040), along with older age and decreased Ccr. Patients with LDO also developed S-1–related non-hematologic toxicity more frequently than those without LDO (p=0.016). Conclusion LDO is a frequent adverse event during S-1 chemotherapy. An older age, decreased Ccr, and high plasma 5-fluorouracil concentration were found to be independent risk factors for LDO. The high incidence of LDO warrants regular ophthalmologic examination and early intervention in patients receiving S-1 therapy.
Abstract
Purpose This prospective study was conducted to determine the incidence of lacrimal drainage obstruction (LDO) during S-1 chemotherapy and evaluate the association between the development of LDO and the concentrations of ingredients/metabolites of S-1 in tears and plasma. Materials and Methods A total of 145 patients with gastric cancer who received adjuvant S-1 therapy were enrolled. Ophthalmologic examinations were performed regularly during S-1 chemotherapy. Concentrations of tegafur, 5-chloro-2,4-dihydroxypyridine (CDHP), and 5-fluorouracil at steady-state trough level were measured in both tears and plasma. Results Fifty-three patients (37%) developed LDO. The median time to the onset of LDO was 10.9 weeks, and LDO developed most frequently in the nasolacrimal duct. Univariable analyses revealed that an older age (! 70 years), creatinine clearance rate (Ccr) < 80 mL/min, 5-fluorouracil concentration in plasma ! 22.3 ng/mL (median), CDHP concentration in plasma ! 42.0 ng/mL (median), and tegafur concentration in tears ! 479.2 ng/mL (median) were related to increased development of LDO. Multivariable analysis indicated that a high plasma 5-fluorouracil concentration was predictive of increased development of LDO (hazard ratio, 2.02; p=0.040), along with older age and decreased Ccr. Patients with LDO also developed S-1–related non-hematologic toxicity more frequently than those without LDO (p=0.016). Conclusion LDO is a frequent adverse event during S-1 chemotherapy. An older age, decreased Ccr, and high plasma 5-fluorouracil concentration were found to be independent risk factors for LDO. The high incidence of LDO warrants regular ophthalmologic examination and early intervention in patients receiving S-1 therapy.
참고문헌 (14)
- Satoh T, "S-1 for the treatment of gastrointestinal cancer", Expert Opin Pharmacother, 13, pp.1943~1959 (2012)[DOI]
- Kim N, "Lacrimal drainage obstruction in gastric cancer patients receiving S-1 chemotherapy", Ann Oncol, 23, pp.2065~2071 (2012)[DOI]
- Kitamura H, "Investigation of epiphora following S-1 therapy", Gan To Kagaku Ryoho, 38, pp.259~262 (2011)
- Sasaki T, "Dacryoendoscopic observation and incidence of canalicular obstruction", stenosis associated with S-1, an oral anticancer drug, 2012, pp.56, 214~218
- Sato K, "Adverse effects of the oral anticancer drug s-1: lacrimal passage impairment and specific features of corneal epitheliopathy", Open Ophthalmol J, 7, pp.85~86 (2013)[DOI]
- Kim SJ, "Safety, compliance, and predictive parameters for dosage modification in adjuvant S-1 chemotherapy for gastric cancer", Cancer Sci, 104, pp.116~123 (2013)[DOI]
- Kim JY, "Impact of intratumoral expression levels of fluoropyrimidinemetabolizing enzymes on treatment outcomes of adjuvant S-1 therapy in gastric cancer", PLoS One, 10, pp.e0120324~ (2015)[DOI]
- Liu K, "Determination of tegafur, 5-fluorouracil, gimeracil and oxonic acid in human plasma using liquid chromatography-tandem mass spectrometry", J Pharm Biomed Anal, 52, pp.550~556 (2010)[DOI]
- Esmaeli B, "Docetaxel secretion in tears: association with lacrimal drainage obstruction", Arch Ophthalmol, 120, pp.1180~1182 (2002)[DOI]
- Christophidis N, "Ocular side effects with 5-fluorouracil", Aust N Z J Med, 9, pp.143~144 (1979)[DOI]
- Loprinzi CL, "Cyclophosphamide, methotrexate, and 5-fluorouracil (CMF)-induced ocular toxicity", Cancer Invest, 8, pp.459~465 (1990)[DOI]
- Esmaeli B, "Canalicular stenosis secondary to docetaxel (taxotere): a newly recognized side effect", Ophthalmology, 108, pp.994~995 (2001)[DOI]
- Paulsen FP, "The cavernous body of the human efferent tear ducts: function in tear outflow mechanism", Invest Ophthalmol Vis Sci, 41, pp.965~970 (2000)
- Thale A, "Functional anatomy of the human efferent tear ducts: a new theory of tear outflow mechanism", Graefes Arch Clin Exp Ophthalmol, 236, pp.674~678 (1998)[DOI]